Pfizer to draw drug from global portfolio
Pfizer India intends to align its business in line with its parent Pfizer Inc. According to the source, the company would draw drugs from it global portfolio, close to the international launches and bring in therapeutic products.
The Indian subsidiary of the pharma major will restructure its field force in alignment with therapeutic products in the coming months. Pfizer, which currently markets around 100 products in India, would launch products of therapeutic value in the cardio vascular, oncology, psychiatry, urology and opthalmology segments in future. There are other generic versions of Viagra in the market, estimated to be about $1.5 million, said Ananthakrishnan, adding that the product is being launched with a hologram of Pfizer on the pack to ensure purchase of original Viagra. The drug being imported from France is available in two doses, 50 mg and 100 mg, priced at Rs 463 and Rs 594 respectively. Viagra so far has been launched in 123 countries and sold over 1.87 billion pills.